APR 2 2 2003 ket No: 368-014

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Kinam Park et al.

Art Unit: 1617

Serial No: 09/975,800

Filed: October 11, 2001

Examiner: E. WebmJECH CENTER 1600/2900

RECEIVE

APR 2 5 2003

For: PHARMACEUTICAL APPLICATIONS: OF HYDROTROPIC AGENTS, POLYMERS: THEREOF AND HYDROGELS THEREOF

RESPONSE TO RESTRICTION REQUIREMENT

Commissioner of Patents PO Box 1450 Alexandria, VA 22313-1450

Sir:

This is in response to the Restriction Requirement mailed February 12, 2003. The petition and fee for a one-month extension of time are forwarded herewith.

Applicants hereby elect with traverse claim set II (claims The elected claims are drawn to 8-20) for prosecution. hydrotropic polymers or copolymers and hydrogels of the present invention. This election is made with traverse inasmuch as the claimed subject matter sets forth that the elected compounds are capable of increasing water solubility of a poorly soluble drug. Accordingly, concurrent examination of those claims relating to utilization of the elected compounds in pharmaceutical

U.S. Serial No. 09/975,800

compositions (claim sets I and III) should not be unduly burdensome inasmuch as it would presumably be nearly coextensive. Similarly, concurrent examination of method of forming claims 28 and 30 (identified as falling within claim set IV) would not be unduly burdensome.

The Restriction Requirement further required an election of species/subgenus of certain dependent claims within claim set

II, in the event of its election. Accordingly, the following elections are made with traverse:

- Claim 9: the elected hydrophobic moiety is "substituted and unsubstituted nitrogen heterocycles";
- Claim 10: the elected arrangement of monomer units is "random";
- Claim 14: the elected hydrotropic agent monomer unit is polymerizable derivatives of "N-substituted nicotinamide";
- Claim 15: the elected hydrotropic agent monomer unit is vinyl derivatives of "N-picolylnicotinamide"; and
- Claim 17: the elected poorly soluble drug is "paclitaxel".

The above elections are made with traverse because concurrent examination of other recited members of the respective Markush groups would not be unduly burdensome.

U.S. Serial No. 09/975,800

If, in the opinion of the Examiner, a telephone conversation could expedite prosecution, the Examiner is invited to telephone the undersigned at the number given below.

Respectfully submitted,

Reg. No. 33,965

Correspondence Address

2804 Kentucky Ave.

Joplin MO 64804 Tel: 417-781-9965

Fax: 503-217-9394

CERTIFICATE OF MAILING

I, James H. Meadows, hereby certify that this correspondence is being deposited on April 14, 2003 with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to:

Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450
Signature: (James H. Meadows)

					b	
OIPE				4	·	
Under the Paperwork Reduction Act of 1995, no persons are requir	red to n	espand t	U.S. Pa	tent an	Approved for use through 04/30/2003. OM d Trademark Office; U.S. DEPARTMENT OF	COMMERCE
					Complete if Known	IVED
FEE TRANSMITTA	ᆸ	Applic	cation N	lumbe	Tables RIFUE	,101-0-
for FY 2003 Effective 01/01/2003. Patent fees are subject to annual revision.		Filing Date			10/11/2001	5 0002
		First Named Inventor		Invent	or K. Park APR 2	5 2005
		Examiner Name				
Applicant claims small entity status. See 37 CFR 1.27		Art U			1617 TECH CENT	ER 1600/2900
TOTAL AMOUNT OF PAYMENT (\$) 55			ney Doc	ket No		
METHOD OF PAYMENT (check all that apply)					CALCULATION (continued)	
Check Credit card Money Other None	3. <i>E</i>	ADDITI	ONAL		•	
Order Order		Entity				
Deposit Account: Deposit	Fee	Fee e (\$)		Fee (\$)	Fee Description	Fee Paid
Account Number	1051		2051		Surcharge - late filing fee or oath	Fee Faid
Deposit	1052	2 50	2052		Surcharge - late provisional filing fee or	
Account Name	1053	3 130	1053		cover sheet Non-English specification	
The Commissioner is authorized to: (check all that apply) Charge fee(s) indicated below Credit any overpayments	1812	2,520	1812 2	,520 F	or filing a request for ex parte reexamination	
Charge any additional fee(s) during the pendency of this application	1804	920*	1804		Requesting publication of SIR prior to Examiner action	
Charge fee(s) indicated below, except for the filing fee	1805	5 1,840*	1805 1		Requesting publication of SIR after	
to the above-identified deposit account.					Examiner action	
FEE CALCULATION	1251 1252		2251 2252		Extension for reply within first month Extension for reply within second month	55
1. BASIC FILING FEE	1252		2253		Extension for reply within third month	100
Large Entity Small Entity Fee Fee Fee Fee Fee Paid Fee Paid	1	1,450	2254		Extension for reply within fourth month	
Code (\$) Code (\$) 1001 750 2001 375 Utility filing fee	1255	1,970	2255	985	Extension for reply within fifth month	
1002 330 2002 165 Design filing fee	1401	1 320	2401	160	Notice of Appeal	<u> </u>
1003 520 2003 260 Plant filing fee	1402	320	2402	160	Filing a brief in support of an appeal	
1004 750 2004 375 Reissue filing fee	1403	3 280	2403	140	Request for oral hearing	
1005 160 2005 80 Provisional filing fee	1	1 1,510	1		Petition to institute a public use proceeding	
SUBTOTAL (1) (\$)	1452		2452		Petition to revive - unavoidable	
2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE		3 1,300 1 1,300	2453 2501		Petition to revive - unintentional Utility issue fee (or reissue)	
Fee from Ext <u>ra Claim</u> s <u>below Fee Paid</u>	1502		2502		Design issue fee	
Total Claims20** = X =	1503	3 630	2503	315	Plant issue fee	
Independent Claims - 3** = X = X	1460	130	1460	130	Petitions to the Commissioner	
Multiple Dependent	1807	7 50	1807		Processing fee under 37 CFR 1.17(q)	
Large Entity Small Entity Fee Fee Fee Fee Fee Description	1806	6 180	1806		Submission of Information Disclosure Stmt	
Code (\$) Code (\$)	8021	1 40	8021	40	Recording each patent assignment per property (times number of properties)	
1202 18 2202 9 Claims in excess of 20 1201 84 2201 42 Independent claims in excess of 3	1809	9 750	2809	375	Filing a submission after final rejection (37 CFR 1.129(a))	
1203 280 2203 140 Multiple dependent claim, if not paid	1810	750	2810	375	For each additional invention to be	
1204 84 2204 42 ** Reissue independent claims	100	1 750	2801	375	examined (37 CFR 1.129(b)) Request for Continued Examination (RCE)	
over original patent 1205 18 2205 9 ** Reissue claims in excess of 20	180 180		1802		Request for expedited examination	
and over original patent	ł				of a design application	└──

**or number previously paid, if greater; For Reissues, see above (Complete (if applicable) SUBMITTED BY Registration No. James H. Meadows Telephone 417-781-9965 Name (Print/Type) (Attorney/Agent) 414 Mendour 4/14/03 Signature

Other fee (specify)

*Reduced by Basic Filing Fee Paid

SUBTOTAL (3)

(\$) 55

and over original patent

(\$)

SUBTOTAL (2)

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.